Yu Mingxing, Zhang Nana, Chen Chunyan, He Yuxuan, Meng Jing, Luo Wen, Liang Yi, Guo Yi, Yu Liang
Chengdu University of Traditional Chinese Medicine, Chengdu, China.
Department of Neurology, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.
Epilepsia Open. 2025 Jun;10(3):822-830. doi: 10.1002/epi4.70038. Epub 2025 Apr 7.
The objective was to assess the effects of perampanel (PER) on bone metabolism and bone mineral density (BMD) in adult patients with epilepsy.
This retrospective study included consecutive patients admitted to the Epilepsy Center of Sichuan Provincial People's Hospital from January 2023 to June 2024. A total of 39 patients who completed bone metabolism and BMD evaluations after 1 year of PER treatment were included in the PER group. The control group comprised 44 patients with newly diagnosed epilepsy. A cross-sectional analysis was conducted between the two groups. We conducted a subgroup analysis of patients stratified by seizure frequency and type. Patients in the PER group were further stratified according to their seizure frequency and seizure type. Finally, we performed a cohort study involving 10 PER-treated patients whose baseline data were available prior to initiating PER therapy.
No significant differences in bone mineral density were observed between the experimental groups and the control group. With respect to bone metabolism, minor alterations were observed only in thyroid hormone levels and serum magnesium concentrations relative to those of the controls. No significant differences in bone metabolism or BMD were observed before or after PER treatment.
Short-term PER treatment did not significantly affect bone mineral density in adult patients with epilepsy.
This study investigated how PER, a drug used to treat epilepsy, affects bone health in adult patients. Researchers compared 39 patients who were treated with PER for 1 year with 44 patients with newly diagnosed epilepsy. They did not observe significant differences in BMD between the two groups. Some minor changes were observed in thyroid hormone and magnesium levels in the blood, but overall, PER treatment did not have a major effect on bone metabolism or BMD. This study suggested that the short-term use of PER does not significantly affect bone health in people with epilepsy.
评估吡仑帕奈（PER）对成年癫痫患者骨代谢和骨密度（BMD）的影响。
这项回顾性研究纳入了2023年1月至2024年6月期间连续入住四川省人民医院癫痫中心的患者。PER组纳入了39例在接受PER治疗1年后完成骨代谢和BMD评估的患者。对照组包括44例新诊断的癫痫患者。对两组进行横断面分析。我们对按癫痫发作频率和类型分层的患者进行了亚组分析。PER组患者进一步根据其癫痫发作频率和发作类型进行分层。最后，我们进行了一项队列研究，涉及10例在开始PER治疗前有可用基线数据的接受PER治疗的患者。
实验组和对照组之间未观察到骨密度的显著差异。关于骨代谢，相对于对照组，仅在甲状腺激素水平和血清镁浓度方面观察到微小变化。在PER治疗前后，骨代谢或BMD均未观察到显著差异。
短期PER治疗对成年癫痫患者的骨密度没有显著影响。
本研究调查了用于治疗癫痫的药物PER如何影响成年患者的骨骼健康。研究人员将39例接受PER治疗1年的患者与44例新诊断的癫痫患者进行了比较。他们未观察到两组之间BMD的显著差异。在血液中的甲状腺激素和镁水平方面观察到了一些微小变化，但总体而言，PER治疗对骨代谢或BMD没有重大影响。这项研究表明，短期使用PER对癫痫患者的骨骼健康没有显著影响。
